The ubiquitin-proteasome system as a drug target in cerebrovascular disease: Therapeutic potential of proteasome inhibitors

Current Opinion in Investigational Drugs

Volumn 6, Issue 7, 2005, Pages 686-699

  Di Napoli, Mario ^a   McLaughlin, BethAnn ^b,c  

^a Neurological Section   (Italy)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Excitotoxicity; Glutamate; Hypoxia inducible transcription factor 1 ; Inflammation; N methyl D aspartate; Neurons; Neurotoxicity; Nuclear factor B; Oxidative stress; Proteasome; Stroke; Ubiquitin

Indexed keywords

CVT 634; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; GLIOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN BETA LACTONE; MEVINOLIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN C FOS; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEINASE INHIBITOR; RITONAVIR; SULFONE DERIVATIVE; TANNIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTOR; UBIQUITIN; UNCLASSIFIED DRUG; VINBLASTINE;

ASTROCYTE; BRAIN HYPOXIA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN NERVE CELL; CELL FATE; CELL GROWTH; CELL METABOLISM; CELL NUCLEUS; CELL PROLIFERATION; CELL REGENERATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; EUKARYOTIC CELL; EXCITOTOXICITY; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; IMMUNOREACTIVITY; NERVE DEGENERATION; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 21344453509     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (160)

1. Caso V, Hacke W: The very acute stroke treatment: Fibrinolysis and after. Clin Exp Hypertens (2002) 24(7-8):595-602.
2. Ikonomidou C, Turski L: Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol (2002) 1(6):383-386.
3. Dirnagl J, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci (1999) 22(9):391-397.
4. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ: Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol (2000) 10(1):95-112.
5. Stanimirovic D, Satoh K: Inflammatory mediators of cerebral endothelium: A role in ischemic brain inflammation. Brain Pathol (2000) 10(1):113-126.
6. Raghavendra Rao VL, Bowen KK, Dhodda VK, Song G, Franklin JL, Gavva NR, Dempsey RJ: Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia. J Neurochem (2002) 83(5):1072-1086.
7. Mattson MP, Camandola S: NF-κB in neuronal plasticity and neurodegenerative disorders. J Clin Invest (2001) 107(3):247-254.
8. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 288(5467):874-877.
9. Suzuki Y, Nakabayashi Y, Takahashi R: Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA (2001) 98(15):8662-8667.
10. Stenzel-Poore MP, Stevens SL, Xiong Z, Lessov NS, Harrington CA, Mori M, Meller R, Rosenzweig HL, Tobar E, Shaw TE, Chu X, Simon RP: Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: Similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet (2003) 362(9389):1028-1037.
11. McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, Aizenman E: Caspase 3 activation is essential for neuroprotection in preconditioning. Proc Natl Acad Sci USA (2003) 100(2):715-720.
12. Golab J, Bauer TM, Daniel V, Naujokat C: Role of the ubiquitin-proteasome pathway in the diagnosis of human diseases. Clin Chim Acta (2004) 340(1-2):27-40.
13. Sherman MY, Goldberg AL: Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron (2001) 29(1):15-32.
14. Fang S, Lorick KL, Jensen JP, Weissman AM: RING finger ubiquitin protein ligases: Implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol (2003) 13(1):5-14.
15. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev (2002) 82(2):373-428.
16. Haglund K, Di Fiore PP, Dikic I: Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci (2003) 28(11):598-603.
17. Hicke L, Dunn R: Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol (2003) 19:141-172.
18. Johnson ES: Protein modification by SUMO. Annu Rev Biochem (2004) 73:355-382.
19. Huang DT, Walden H, Duda D, Schulman BA: Ubiquitin-like protein activation. Oncogene (2004) 23(11):1958-1971.
20. Brooks CL, Li M, Gu W: Monoubiquitination: The signal for p53 nuclear export? Cell Cycle (2004) 3(4):436-438.
21. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ: Activation of the lκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell (2000) 103(2):351-361.
22. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature (2001) 411(6835):355-365.
23. Shtiegman K, Yarden Y: The role of ubiquitylation in signalling by growth factors: Implications to cancer. Semin Cancer Biol (2003) 13(1):29-40.
24. Marmor MD, Yarden Y: Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene (2004) 23(11):2057-2070.
25. Bache KG, Slagsvold T, Stenmark H: Defective downregulation of receptor tyrosine kinases in cancer. EMBO J (2004) 23(14):2707-2712.
26. Cong F, Zhang J, Pao W, Zhou P, Varmus H: A protein knockdown strategy to study the function of β-catenin in tumorigenesis. BMC Mol Biol (2003) 4(1):10.
27. Zhang J, Zheng N, Zhou P: Exploring the functional complexity of cellular proteins by protein knockout. Proc Natl Acad Sci USA (2003) 100(24):14127-14132.
28. Pickart CM: Back to the future with ubiquitin. Cell (2004) 116(2):181-190.
29. Ciechanover A: The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J(1998) 17(24):7151-7160.
30. van Kerkhof P, Alves dos Santos CM, Sachse M, Klumperman J, Bu G, Strous GJ: Proteasome inhibitors block a late step in lysosomal transport of selected membrane but not soluble proteins. Mol Biol Cell (2001) 12(8):2556-2566.
31. Fisk HA, Yaffe MP: A role for ubiquitination in mitochondrial inheritance in Saccharomyces cerevisiae. J Cell Biol (1999) 145(6):1199-1208.
32. Spence J, Gall RR, Dittmar G, Sherman F, Karin M, Finley D: Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell (2000) 102(1):67-76.
33. Spence J, Sadis S, Haas AL, Finley D: A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol Cell Biol (1995) 15(3):1265-1273.
34. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ: TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature (2001) 412(6844):346-351.
35. Hicke L: A new ticket for entry into budding vesicles-ubiquitin. Cell (2001) 106(5):527-530.
36. Pickart CM: Mechanisms underlying ubiquitination. Annu Rev Biochem (2001) 70:503-533.
37. Orlowski M, Cardozo C, Michaud C: Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry (1993) 32(6):1563-1572.
38. Kierszenbaum AL: The 26S proteasome: Ubiquitin-mediated proteolysis in the tunnel. Mol Reprod Dev (2000) 57(2):109-110.
39. Bury M, Mlynarczuk I, Pleban E, Hoser G, Kawiak J, Wojcik C: Effects of an inhibitor of tripeptidyl peptidase II (Ala-Ala-Phe-chloromethylketone) and its combination with an inhibitor of the chymotrypsin-like activity of the proteasome (PSI) on apoptosis, cell cycle and proteasome activity in U937 cells. Folia Histochem, Cytobiol (2001) 39(2):131-132.
40. Wang EW, Kessler BM, Borodovsky A, Cravatt BF, Bogyo M, Ploegh HL, Glas R: Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity. Proc Natl Acad Sci USA (2000) 97(18):9990-9995.
41. Di Napoli M, Papa F: The proteasome system and proteasome inhibitors in stroke: Controlling the inflammatory response. Curr Opin Invest Drugs (2003) 4(11):1333-1342.
42. Asai A, Tanahashi N, Qiu JH, Saito N, Chi S, Kawahara N, Tanaka K, Kirino T: Selective proteasomal dysfunction in the hippocampal CA1 region after transient forebrain ischemia. J Cereb Blood Flow Metab (2002) 22(6):705-710.
43. Wojcik C, Di Napoli M: Ubiquitin-proteasome system and proteasome inhibition: New strategies in stroke therapy. Stroke (2004) 35(6):1506-1518.
44. Kim CH, Kim JH, Hsu CY, Ahn YS: Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-κB activation. FEBS Lett (1999) 449(1):28-32.
45. Kamikubo T, Hayashi T: Changes in proteasome activity following transient ischemia. Neurochem Int (1996) 28(2):209-212.
46. Gubellini P, Bisso GM, Ciofi-Luzzatto A, Fortuna S, Lorenzini P, Michalek H, Scarsella G: Ubiquitin-mediated stress response in a rat model of brain transient ischemia/hypoxia. Neurochem Res (1997) 22(l):93-100.
47. Vannucci SJ, Mummery R, Hawkes RB, Rider CC, Beesley PW: Hypoxia-ischemia induces a rapid elevation of ubiquitin conjugate levels and ubiquitin immunoreactivity in the immature rat brain. J Cereb Blood Flow Metab (1998) 18(4):376-385.
48. Magnusson K, Wieloch T: Impairment of protein ubiquitination may cause delayed neuronal death. Neurosci Lett (1989) 96(3):264-270.
49. Ding Q, Bruce-Keller AJ, Chen Q, Keller JN: Analysis of gene expression in neural cells subject to chronic proteasome inhibition. Free Radic Biol Med (2004) 36(4):445-455.
50. Hu BR, Janelidze S, Ginsberg MD, Busto R, Perez-Pinzon M, Sick TJ, Siesjo BK, Liu CL: Protein aggregation after focal brain ischemia and reperfusion. J Cereb Blood Flow Metab (2001) 21(7):865-875.
51. Hu BR, Martone ME, Jones YZ, Liu CL: Protein aggregation after transient cerebral ischemia. J Neurosci (2000) 20(9):3191-3199.
52. Tytell M, Brown WR, Moody DM, Challa VR: Immunohistochemical assessment of constitutive and inducible heat-shock protein 70 and ubiquitin in human cerebellum and caudate nucleus. Mol Chem Neuropathol (1998) 35(1-3):97-117.
53. Noga M, Hayashi T, Tanaka J: Gene expressions of ubiquitin and Hsp70 following focal ischaemia in rat brain. Neuroreport (1997) 8(5):1239-1241.
54. Hara T, Mies G, Hata R, Hossmann KA: Gene expressions after thrombolytic treatment of middle cerebral artery clot embolism in mice. Stroke (2001) 32(8):1912-1919.
55. Nowak TS Jr, Bond U, Schlesinger MJ: Heat shock RNA levels in brain and other tissues after hyperthermia and transient ischemia. J Neurochem (1990) 54(2):451-458.
56. Welch WJ: Heat shock proteins functioning as molecular chaperones: Their roles in normal and stressed cells. Philos Trans Soc Lond Biol (1993) 339(1289):327-333.
57. Yenari MA, Giffard RG, Sapolsky RM, Steinberg GK: The neuroprotective potential of heat shock protein 70 (Hsp70). Mol Med Today (1999) 5(12):525-531.
58. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol (2000) 2(8):469-475.
59. Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES: Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol (2000) 2(8):476-483.
60. Lee JE, Yenari MA, Sun GH, Xu L, Emond MR, Cheng D, Steinberg GK, Giffard RG: Differential neuroprotection from human heat shock protein 70 overexpression in in vitro and in vivo models of ischemia and ischemia-like conditions. Exp Neurol (2001) 170(1):129-139.
61. L or Hsp70 in murine cortical astrocytes reduces injury of co-cultured neurons. Neurosci Lett (1999) 277(3):193-197.
62. Hoehn B, Ringer TM, Xu L, Giffard RG, Sapolsky RM, Steinberg GK, Yenari MA: Overexpression of Hsp72 after induction of experimental stroke protects neurons from ischemic damage. J Cereb Blood Flow Metab (2001) 21(11):1303-1309.
63. Cyr DM, Hohfeld J, Patterson C: Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem Sci (2002) 27(7):368-375.
64. Imai Y, Soda M, Hatakeyama S, Akagi T, Hashikawa T, Nakayama KI, Takahashi R: CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell (2002) 10(1):55-67.
65. Shimura H, Schwartz D, Gygi SP, Kosik KS: CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem (2004) 279(6):4869-4876.
66. Meacham GC, Patterson C, Zhang W, Younger JM, Cyr DM: The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol (2001) 3(1):100-105.
67. Imai Y, Soda M, Murakami T, Shoji M, Abe K, Takahashi R: A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J Biol Chem (2003) 278(51):51901-51910.
68. Maraganore DM, de Andrade M, Lesnick TG, Farrer MJ, Bower JH, Hardy JA, Rocca WA: Complex interactions in Parkinson's disease: A two-phased approach. Mov Disord(2003) 18(6):631-636.
69. Song S, Kim SY, Hong YM, Jo DG, Lee JY, Shim SM, Chung CW, Seo SJ, Yoo YJ, Koh JY, Lee MC et al: Essential role of E2-25K/Hip-2 in mediating amyloid-β neurotoxicity. Mol Cell (2003) 12(3):553-563.
70. McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW: Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem (2002) 81(2):301-306.
71. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD: Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene (2004) 23(11):2009-2015.
72. Takayama S, Reed JC: Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol (2001) 3(10):237-241.
73. Kalia SK, Lee S, Smith PD, Liu L, Crocker SJ, Thorarinsdottir TE, Glover JR, Fon EA, Park DS, Lozano AM: BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron (2004) 44(6):931-945.
74. Tanaka S, Uehara T, Nomura Y: Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. J Biol Chem (2000) 275(14):10388-10393.
75. Schmidt-Kastner R, Zhang BT, Webster K, Kietzmann T, Zhao W, Busto R, Ginsberg MD: Hypoxia-inducible factor-1 (HIF-1) in experimental brain ischemia. Scientific World J (2002) 2:123-124.
76. Richard S, Campello C, Taillandier L, Parker F, Resche F: Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French vHL Study Group. J Intern Med (1998) 243(6):547-553.
77. Nakayama K, Frew IJ, Hagensen M, Skals M, Halbelhah H, Bhoumik A, Kadoya T, Erdjument-Bromage H, Tempst P, Frappell PB: Siah2 regulates stability of prolyl-hydroxylases, controls HIF1α abundance, and modulates physiological responses to hypoxia. Cell (2004) 117(7):941-952.
78. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L: Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem (1999) 274(10):6519-6525.
79. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, Hampton TG et al: PR39, a peptide regulator of angiogenesis. Nat Med (2000) 6(1):49-55.
80. Soucek T, Cumming R, Dargusch R, Maher P, Schubert D: The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid β peptide. Neuron (2003) 39(1):43-56.
81. Lam YA, Lawson TG, Velayutham M, Zweier JL, Pickart CW: A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature (2002) 416(6882):763-767.
82. Lee C, Schwartz MP, Prakash S, Iwakura M, Matouschek A: ATP-dependent proteases degrade their substrates by processively unraveling them from the degradation signal. Mol Cell (2001) 7(3):627-637.
83. Mengesdorf T, Jensen PH, Mies G, Aufenberg C, Paschen W: Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease? Proc Natl Acad Sci USA (2002) 99(23):15042-15047.
84. Hampton MB, Fadeel B, Orrenius S: Redox regulation of the caspases during apoptosis. Ann NY Acad Sci (1998) 854:328-335.
85. Amici M, Forti K, Nobili C, Lupidi G, Angeletti M, Fioretti E, Eleuteri AM: Effect of neurotoxic metal ions on the proteolytic activities of the 20S proteasome from bovine brain. J Biol Inorg Chem (2002) 7(7-8):750-756.
86. Fruh K, Gossen M, Wang K, Bujard H, Peterson PA, Yang Y: Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: A newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J (1994) 13(14):3236-3244.
87. Hershko A: Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol (1997) 9(6):788-799.
88. Peng TI, Jou MJ, Sheu SS, Greenamyre JT: Visualization of NMDA receptor-induced mitochondrial calcium accumulation in striatal neurons. Exp Neurol (1998) 149(1):1-12.
89. Dugan LL, Sensi SL, Canzoniero LM, Handran SD, Rothman SM, Lin TS, Goldberg MP, Choi DW: Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neurosci (1995) 15(10):6377-6388.
90. Mattson MP: Excitotoxic and excitoprotective mechanisms: Abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med (2003) 3(2):65-94.
91. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH: Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA (1991) 88(14):6368-6371.
92. Siman R, Noszek JC, Kegerise C: Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci (1989) 9(5):1579-1590.
93. Dumuis A, Sebben M, Haynes L, Pin JP, Bockaert J: NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature (1988) 336(6194):68-70.
94. Stanciu M, Wang Y, Kentor R, Burke N, Watkins S, Kress G, Reynolds I, Klann E, Angiolieri MR, Johnson JW, DeFranco DB: Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem (2000) 275(16):12200-12206.
95. Reynolds IJ, Hastings TG: Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci (1995) 15(1):3318-3327.
96. Wagenknecht B, Hermisson M, Groscurth P, Liston P, Krammer PH, Weller M: Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome C release. J Neurochem (2000) 75(6):2288-2297.
97. Ling YH, Liebes L, Zou Y, Perez-Soler R: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem (2003) 278(36):33714-33723.
98. Ding Q, Keller JN: Proteasomes and proteasome inhibition in the central nervous system. Free Radic Biol Med (2001) 31(5):574-584.
99. Qiu JH, Asai A, Chi S, Saito N, Hamada H, Kirino T: Proteasome inhibitors induce cytochrome C-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J Neurosci (2000) 20(1):259-265.
100. Bobba A, Canu N, Atlante A, Petragallo V, Calissano P, Marra E: Proteasome inhibitors prevent cytochrome C release during apoptosis but not in excitotoxic death of cerebellar granule neurons. FEBS Lett (2002) 515(1-3):8-12.
101. Colledge M, Snyder EM, Crozier RA, Soderling JA, Jin Y, Langeberg LK, Lu H, Bear MF, Scott JD: Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron (2003) 40(3):595-607.
102. Ehlers MD: Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci (2003) 6(3):231-242.
103. Ehrlich I, Malinow R: Postsynaptic density 95 controls AMPA receptor incorporation during long-term potentiation and experience-driven synaptic plasticity. J Neurosci (2004) 24(4):916-927.
104. Liu CL, Martone ME, Hu BR: Protein ubiquitination in postsynaptic densities after transient cerebral ischemia. J Cereb Blood Flow Metab (2004) 24(11):1219-1225.
105. + channel Kir 2.3 to PSD-95 is regulated by protein kinase A phosphorylation. Neuron (1996) 17(4):759-767.
106. Suen PC, Wu K, Xu JL, Lin SY, Levine ES, Black IB: NMDA receptor subunits in the postsynaptic density of rat brain: Expression and phosphorylation by endogenous protein kinases. Brain Res Mol Brain Res (1998) 59(2):215-228.
107. Arundine M, Tymianski M: Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium (2003) 34(4-5):325-337.
108. Snider BJ, Tee LY, Canzoniero LM, Babcock DJ, Choi DW: NMDA antagonists exacerbate neuronal death caused by proteasome inhibition in cultured cortical and striatal neurons. Eur J Neurosci (2002) 15(3):419-428.
109. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B, Szweda LI: Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem (2001) 276(32):30057-30063.
110. Carrard G, Bulteau AL, Petropoulos I, Friguet B: Impairment of proteasome structure and function in aging. Int J Biochem Cell Biol (2002) 34(11):1461-1474.
111. Grune T, Merker K, Sandig G, Davies KJ: Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun (2003) 305(3):709-718.
112. Shringarpure R, Grune T, Mehlhase J, Davies KJ: Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem (2003) 278(1):311-318.
113. Demasi M, Davies KJ: Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen-dependent mechanism. FEBS Lett (2003) 542(1-3):89-94.
114. Thornberry NA, Lazebnik Y: Caspases: Enemies within. Science (1998) 281(5381):1312-1316.
115. Fischer U, Janicke RU, Schulze-Osthoff K: Many cuts to ruin: A comprehensive update of caspase substrates. Cell Death Differ (2003) 10(1):76-100.
116. Benchoua A, Guegan C, Couriaud C, Hosseini H, Sampaio N, Morin D, Onteniente B: Specific caspase pathways are activated in the two stages of cerebral infarction. J Neurosci (2001) 21(18):7127-7134.
117. Friedlander RM, Gagliardini V, Hara H, Fink KB, Li W, MacDonald G, Fishman MC, Greenberg AH, Moskowitz MA, Yuan J: Expression of a dominant negative mutant of interleukin-1β converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp Med (1997) 185(5):933-940.
118. Trapp T, Korhonen L, Besselmann M, Martinez R, Mercer EA, Lindholm D: Transgenic mice overexpressing XIAP in neurons show better outcome after transient cerebral ischemia. Mol Cell Neurosci (2003) 23(2):302-313.
119. Hara H, Fink K, Endres M, Friedlander RM, Gagliardini V, Yuan J, Moskowitz MA: Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J Cereb Blood Flow Metab (1997) 17(4):370-375.
120. Fink K, Zhu J, Namura S, Shimizu-Sasamata M, Endres M, Ma J, Dalkara T, Yuan J, Moskowitz MA: Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J Cereb Blood Flow Metab (1998) 18(10):1071-1076.
121. Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM: Caspase activation inhibits proteasome function during apoptosis. Mol Cell (2004) 14(1):81-93.
122. Haddad JJE, Olver RE, Land SC: Antioxidant/pro-oxidant equilibrium regulates HIF-1α and NF-κB redox sensitivity. Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. J Biol Chem (2000) 275(28):21130-21139.
123. Delhase M, Hayakawa M, Chen Y, Karin M: Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science (1999) 284(5412):309-313.
124. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol (2000) 18:621-663.
125. Celec P: Nuclear factor κB - molecular biomedicine: The next generation. Biomed Pharmacother (2004) 58(6-7):365-371.
126. Epinat J-C, Gilmore TD: Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene (1999) 18(49):6896-6909.
127. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC: Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke (2000) 31(7):1686-1693.
128. Salminen A, Liu PK, Hsu CY: Alteration of transcription factor binding activities in the ischemic rat brain. Biochem Biophys Res Commun (1994) 212(3):939-944.
129. Williams AJ, Hale SL, Moffett JR, Dave JR, Elliott PJ, Adams J, Tortella FC: Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-κB activation, gliosis, and leukocyte infiltration. J Cereb Blood Flow Metab (2003) 23(1):75-87.
130. Kisselev AF, Goldberg AL: Proteasome inhibitors: From research tools to drug candidates. Chem Biol (2001) 8(8):739-758.
131. Lee DH, Goldberg AL: Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol (1998) 8(10):397-403.
132. Groll M, Koguchi Y, Huber R, Kohno J: Crystal structure of the 20 S proteasome:TMC-95A complex: A non-covalent proteasome inhibitor. J Mol Biol (2001) 311(3):543-548.
133. Kessler BM, Tortorella D, Altun M, Kisselev AF, Fiebiger E, Hekking BG, Ploegh HL, Overkleeft HS: Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic β-subunits. Chem Biol (2001) 8(9):913-929.
134. Meng L, Kwok BH, Sin N, Crews CM: Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res (1999) 59(12):2798-2801.
135. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA (1999) 96(18):10403-10408.
136. Kroll M, Arenzana-Seisdedos F, Bachelerie F, Thomas D, Friguet B, Conconi M: The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem Biol (1999) 6(10):689-698.
137. Nam S, Smith DM, Dou QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem (2001) 276(16):13322-13330.
138. 1 arrest and apoptosis. Cancer Epidemiol Biomarkers Prev (2001) 10(10):1083-1088.
139. Andre P, Groettrup M, Klenerman P, de Giuli R, Booth BL Jr, Cerundolo V, Bonneville M, Jotereau F, Zinkernagel RM, Lotteau V: An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA (1998) 95(22):13120-13124.
140. Kiyomiya K, Matsuo S, Kurebe M: Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. Life Sci (1998) 62(20):1853-1860.
141. Piccinini M, Tazartes O, Mezzatesta C, Ricotti E, Bedino S, Grosso F, Dianzani U, Tovo PA, Mostert M, Musso A, Rinaudo MT: Proteasomes are a target of the anti-tumour drug vinblastine. Biochem J (2001) 356(3):835-841.
142. Berti R, Williams AJ, Velarde LC, Moffett JR, Elliott PJ, Adams J, Yao C, Dave JR, Tortella FC: Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat. Neurotox Res (2003) 5(7):505-514.
143. Williams AJ, Berti R, Dave JR, Elliot PJ, Adams J, Tortella FC: Delayed treatment of ischemia/reperfusion brain injury: extended therapeutic window with the proteosome inhibitor MLN519. Stroke (2004) 35(5):1186-1191.
144. Buchan AM, Li H, Blackburn B: Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-κB activation. Neuroreport (2000) 11(2):427-430.
145. Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ, Chopp M: Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke (2001) 32(12):2926-2931.
146. Di Napoli M, Papa F: MLN-5119. Millennium/PAION. Curr Opin Invest Drugs (2003) 4(3):333-341.
147. Bailey CK, Andriola IF, Kampinga HH, Merry DE: Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet (2002) 11(5):515-523.
148. Halliwell B: Hypothesis: Proteasomal dysfunction: A primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death. Ann NY Acad Sci (2002) 962:182-194.
149. Jenner P: Oxidative stress in Parkinson's disease. Ann Neurol (2003) 53(Suppl 3):S26-S36.
150. Mayer RJ: From neurodegeneration to neurohomeostasis: The role of ubiquitin. Drug News Perspect (2003) 16(2):103-108.
151. Elliott PJ, Zollner TM, Boehncke WH: Proteasome inhibition: A new anti-inflammatory strategy. J Mol Med (2003) 81(4):235-245.
152. Keller JN, Markesbery WR: Proteasome inhibition results in increased poly-ADP-ribosylation: Implications for neuron death. J Neurosci Res (2000) 61(4):436-442.
153. Kikuchi S, Shinpo K, Takeuchi M, Tsuji S, Yabe I, Niino M, Tashiro K: Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons. J Neurosci Res (2002) 69(3):373-381.
154. Wojcik C: Regulation of apoptosis by the ubiquitin and proteasome pathway. J Cell Mol Med (2002) 6(1):25-48.
155. Zund G, Uezono S, Stahl GL, Dzus AL, McGowan FX, Hickey PR, Colgan SP: Hypoxia enhances induction of endothelial ICAM-1: Role for metabolic acidosis and proteasomes. Am J Physiol (1997) 273(5 Pt 1):C1571-C1580.
156. Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer (2004) 4(5):349-360.
157. Shah IM, Lees KR, Pien CP, Elliott PJ: Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol (2002) 54(3):269-276.
158. Millennium Pharmaceuticals Inc: Research and Development day. Company Presentation (2004): November 16.
159. Kopito RR: Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol (2000) 10(12):524-530.
160. Lindsten K, Menendez-Benito V, Masucci MG, Dantuma NP: A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol (2003) 21(8):897-902.